Pinnacle Clinical Research

Pinnacle Clinical Research

Founded as an independent clinical trial site network, Pinnacle Clinical Research built its operating model around owning and managing the physical infrastructure where drug studies actually take place. The firm recruits principal investigators, maintains patient databases, and handles the regulatory and logistical burdens that pharmaceutical sponsors and contract research organizations typically outsource. This direct operational footprint distinguishes it from the capital-allocation or advisory structures common in healthcare private equity. Pinnacle's trial portfolio concentrates on non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatotic liver disease (MASLD), and broader gastroenterology indications — therapeutic areas where patient recruitment complexity creates high barriers to entry for less specialized sites. The firm runs studies from first-in-human Phase I through registrational Phase III programs, functioning as an in-network partner for large pharmaceutical sponsors seeking repeatable, high-enrollment performance. Its geographic footprint spans multiple clinical locations in Texas, with additional sites extending into other US regions to diversify patient demographics and investigator expertise. Team scale and ownership structure remain private, consistent with a closely held services business that has not sought public capital or disclosed organizational headcount. The firm maintains an active pipeline of enrolling trials visible to patients and referring physicians, which signals operational continuity rather than episodic project work. No adjacent investment vehicles, philanthropic foundations, or club membership disclosures have been identified in public record. What separates Pinnacle structurally from asset managers or family offices operating in healthcare is the absence of a financial returns mandate reported to limited partners. The entity is an operating services company, not a fund — its revenue comes from trial execution, not capital deployment. That posture places it in the same structural category as Ellen Morgan's Javara or Jeff Kingsley's IACT Health: scaled clinical trial infrastructure companies that specialize in the operational layer between drug sponsors and patients.